Management of non alcoholic fatty liver disease in Ayurveda

A comparative study of Agpideepan & Vyadhipratyannek chikitsa with Vyadhipmtyannek chikitsa in the management of Non alcoholic fatty liver

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/06/043419

Enrollment

Registered

2022-06-22

Start date

Unknown

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified Health Condition 2: K760- Fatty (change of) liver, not elsewhere classified Health Condition 3: K760- Fatty (change of) liver, not elsewhere classified Health Condition 4: E888- Other specified metabolic disorders

Interventions

Intervention1: Chitrakadi vati : Chitrakafi vati 2tab BD before food for 3 months Control Intervention1: Phaltrikadi kasaya ghan vati(PTK): Phaltrikadi kasayaghan vati(PTK) 2 tablets twice a day aft

Eligibility

Inclusion criteria

Inclusion criteria: 1. Either sex aged between 18-65 years. 2. Diagnosed cases of Grade- I&II of non-alcoholic fatty liver disease as evident by fatty infiltration by Ultrasound evaluation (USG Abdomen) 3. Participants having BMI from 18.5 to 30 4. Subjects of non-alcoholic fatty liver disease with their hepatic enzymes 5. Willing to provide informed consent and able to participate for 3 months in the study.

Exclusion criteria

Exclusion criteria: 1. Any other identified cause of chronic liver disease or already taking supplementary medicine for NAFLD. 2. H/O habitual consumption of alcohol intake of >20g/day for women, >40g/day for men 3. Subjects who have a past history of Cardiac Arrhythmia, Acute Coronary Syndrome, Myocardial Infarction, Stroke or Severe Arrhythmia in the last 6 months. 4. Known case of malignancy, concurrent Renal Dysfunction, uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients), Neurological disorders, severe psychiatric disorders, endocrinology or other concurrent severe disease. 5. Uncontrolled Diabetes Mellitus(HbA1C >8) 6. Subjects taking participation in any other clinical trial. 7. Pregnant or lactating women 8. Any other condition which PI think can jeopardize the study

Design outcomes

Primary

Measure	Time frame
Change in score of Fatty Liver Index (FLI)Timepoint: baseline and at the end of treatment (90 days)	—

Secondary

Measure	Time frame
to assess changes in ALT AST Serum bilirubin Total proteins & Alkaline Phosphatase. Changes in triglyceride Change in BMI change in Fatty liver index, quality of life in terms of SF 36 score and to assess any biological intolerability or adverse events and to record the number of participants with any biological intolerability or adverse event during the trial period.Timepoint: baseline and at the end of treatment (90 days).	—

Measure

Time frame

to assess changes in ALT AST Serum bilirubin Total proteins & Alkaline Phosphatase. Changes in triglyceride Change in BMI change in Fatty liver index, quality of life in terms of SF 36 score and to assess any biological intolerability or adverse events and to record the number of participants with any biological intolerability or adverse event during the trial period.Timepoint: baseline and at the end of treatment (90 days).

—

Countries

India

Contacts

Public ContactDrBharti

CARICD New Delhi

drbharti@gmail.com9868109737

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026